argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2025-11-20)

EUR 803.00+0.70%

argenx SE
UMushroom community rating:

4.77 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Total Operating Income

argenx SE achieved a total operating income of $1.775 billion for the six months ended June 30, 2025, marking a substantial increase from $902 million in the same period in 2024.

Product Net Sales Growth

The company reported product net sales of $1.739 billion for VYVGART and VYVGART SC, nearly doubling from $876 million in the first half of 2024. This 98% year-over-year growth underscores the strong market demand and expanded patient reach.

Increase in Operating Expenses

Total operating expenses rose to $1.435 billion in the first six months of 2025, up from $1.041 billion in 2024. This increase was primarily due to higher costs of sales, research and development, and selling, general, and administrative expenses.

Research and Development Investments

Research and development expenses surged to $637 million compared to $450 million in the previous year, reflecting argenx SE's commitment to advancing its pipeline and supporting clinical trials across multiple indications.

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses increased to $601 million in the first half of 2025 from $492 million in 2024, driven by expanded marketing efforts and operational scaling to support growth initiatives.

Summarized from source with an LLMView Source

Key figures

45.1%1Y

125%3Y

257%5Y

Performance

34.0%1Y

39.7%3Y

39.4%5Y

Volatility